Agile Therapeutics (NASDAQ:AGRX) – Cantor Fitzgerald issued their FY2019 earnings per share estimates for shares of Agile Therapeutics in a research note issued to investors on Tuesday, April 3rd. Cantor Fitzgerald analyst W. Tanner expects that the specialty pharmaceutical company will post earnings of ($0.65) per share for the year. Cantor Fitzgerald currently has a “Buy” rating and a $5.00 price objective on the stock.
Agile Therapeutics (NASDAQ:AGRX) last posted its quarterly earnings data on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.05.
A number of other equities analysts have also weighed in on AGRX. Noble Financial reissued a “buy” rating on shares of Agile Therapeutics in a research report on Wednesday, March 14th. HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of Agile Therapeutics in a research report on Tuesday, March 13th. Janney Montgomery Scott lowered shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a research report on Thursday, December 28th. Finally, William Blair downgraded shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $9.00.
NASDAQ:AGRX opened at $2.67 on Friday. The company has a market capitalization of $98.29, a PE ratio of -2.93 and a beta of 2.13. Agile Therapeutics has a 1-year low of $1.93 and a 1-year high of $5.60.
A number of institutional investors have recently added to or reduced their stakes in the stock. Perceptive Advisors LLC purchased a new stake in Agile Therapeutics in the fourth quarter valued at approximately $9,092,000. Franklin Resources Inc. grew its holdings in Agile Therapeutics by 3.4% in the fourth quarter. Franklin Resources Inc. now owns 2,867,800 shares of the specialty pharmaceutical company’s stock valued at $7,714,000 after purchasing an additional 95,600 shares during the period. Renaissance Technologies LLC grew its holdings in Agile Therapeutics by 313.7% in the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock valued at $985,000 after purchasing an additional 277,600 shares during the period. Broadfin Capital LLC purchased a new stake in Agile Therapeutics in the fourth quarter valued at approximately $964,000. Finally, Bank of New York Mellon Corp grew its holdings in Agile Therapeutics by 113.1% in the fourth quarter. Bank of New York Mellon Corp now owns 38,920 shares of the specialty pharmaceutical company’s stock valued at $105,000 after purchasing an additional 20,654 shares during the period. Hedge funds and other institutional investors own 71.03% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/analysts-offer-predictions-for-agile-therapeutics-fy2019-earnings-agrx.html.
Agile Therapeutics Company Profile
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.